Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • NPPA Fixes Retail...

NPPA Fixes Retail Price Of 41 Formulations; Details

Medical Dialogues TeamWritten by Medical Dialogues Team Published On 2021-03-19T13:44:18+05:30  |  Updated On 19 Oct 2023 5:20 PM IST
NPPA Fixes Retail Price Of 41 Formulations; Details
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the price of 41 formulations, including those used to treat heart attacks, hypertension, infections, allergies, type 2 diabetes, depression, and anxiety.

These include Macleod's Telmisartan and Hydrochlorothiazidel combination (MACSART H 80 & TELMIDUCE H 80), Telmisartan and Amlodipine combination (MACSART AM 80 & TELMIDUCE AM 80), Metformin and Gliclazide combination (MEFOMIN-GZ 60) among others.

In addition to this, the list also includes Akums, Mylan's Cefixime and Ofloxacin combination, Synokem, Cipla's Azelnidipine plus Telmisartan combination, Synokem or Aristo's Atorvastatin plus Clopidogrel plus Aspirin combination capsule.

This comes after in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (NPPA), fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Sl. No

.

Name of the

Formulation / Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail

Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

1.

Telmisartan + Amlodipine + Hydrochlorothiazide Tablet

Each film coated tablet contains: Telmisartan IP 40mg, Amlodipine Besylate IP eq. to Amlodipine 5mg

Hydrochlorothiazide IP 12.5mg

1 Tablet

M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd.

9.02

2.

Dexamethasone

+Chloramphenicol Eye Drops

Each ml contains: Dexamethasone Sodium Phosphate IP eq. to

Dexamethasone 0.1%w/v, Chloramphenicol IP 1% w/v,

1 ML

M/s Skymap Healthcare Pvt. Ltd. / M/s Albert David Limited

4.09

3.

Dexamethasone

+Chloramphenicol Eye Drops

Each ml contains: Dexamethasone Sodium Phosphate IP eq. to Dexamethasone 0.1%w/v,

Chloramphenicol IP 1% w/v,

1 ML

M/s Skymap Healthcare Pvt. Ltd.

4.09

4.

Telmisartan & Metoprolol Succinate (ER) Tablet

Each uncoated bilayered tablet contains:

Telmisartan IP 40mg,

Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg

(As Extended Release form)

1 Tablet

M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd.

11.22

5.

Telmisartan & Metoprolol Succinate (ER) Tablet

Each uncoated bilayered tablet contains:

Telmisartan IP 40mg,

Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (As Extended Release form)

1 Tablet

M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd.

11.22

6.

Telmisartan, Amlodipine & Hydrochlorothiazide Tablet

Each film coated tablet contains: Telmisartan IP 40mg, Amlodipine Besylate IP eq. to Amlodipine 5mg,

Hydrochlorothiazide IP 12.50 mg

1 Tablet

M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd.

9.02

Sl. No

.

Name of the

Formulation / Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail

Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

7.

Paracetamol, Phenylephrine Hydrochloride , Caffeine & Diphenhydramine Tablet

Each film coated tablet contains: Paracetamol IP 500mg, Phenylephrine Hydrochloride IP 5mg,

Caffeine (Anhydrous) IP 30mg Diphenhydramine Hydrochloride IP

25mg

1 Tablet

M/s Skymap Pharmaceuticals Pvt. Ltd.

2.99

8.

Telmisartan + Cilnidipine + Metoprolol (ER) Tablet

Each film coated Bilayered tablet contains:

Telmisartan IP 40mg, Cilnidipine IP 10mg

Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate (as

extended release) 25mg

1 Tablet

M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Glenmark Pharmaceuticals Ltd.

10.16

9.

Telmisartan + Cilnidipine + Metoprolol (ER) Tablet

Each film coated Bilayered tablet contains:

Telmisartan IP 40mg, Cilnidipine IP 10mg

Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate (as

extended release) 50mg

1 Tablet

M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Glenmark Pharmaceuticals Ltd.

12.41

10.

Telmisartan + Hydrochlorothiazidel Tablet (MACSART H 80 & TELMIDUCE H

80)

Each uncoated bilayered tablet contains:

Telmisartan IP 80mg, Hydrochlorothiazide IP 12.50mg

1 Tablet

M/s Macleods Pharmaceuticals Ltd.

14.00

11.

Telmisartan + Amlodipine Tablet (MACSART AM 80 & TELMIDUCE AM 80)

Each uncoated bilayered tablet contains:

Telmisartan IP 80mg,

Amlodipine Besylate IP eq. to Amlodipine 5mg

1 Tablet

M/s Macleods Pharmaceuticals Ltd.

12.50

12.

Metformin + Gliclazide Tablet (MEFOMIN-GZ 60)

Each uncoated bilayered tablet contains:

Metformin Hydrochloride IP 500mg (as Extended Release form), Gliclazide IP 60mg (as Extended

Release form),

1 Tablet

M/s Macleods Pharmaceuticals Ltd.

9.74

13.

Telmisartan + Cilnidipine + Metoprolol (ER) Tablet (NEXOVAS TM 25)

Each film coated Bilayered tablet contains:

Telmisartan IP 40mg, Cilnidipine IP 10mg

Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate (as

extended release) 25mg

1 Tablet

M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd.

10.16

14.

Atorvastatin + Clopidogrel + Aspirin Capsule

Each Hard gelatine capsule contains:

Atorvastatin calcium IP eq. to Atorvastatin 10mg (As Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets), Aspirin IP 75mg (As enteric coated

pellets)

1

Capsule

M/s Synokem Pharmaceuticals Ltd.

/ M/s Aristo Pharmaceuticals Private Limited.

4.16

Sl. No

.

Name of the

Formulation / Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail

Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

15.

Atorvastatin + Clopidogrel + Aspirin Capsule

Each Hard gelatine capsule contains:

Atorvastatin calcium IP eq. to Atorvastatin 20mg (As Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets), Aspirin IP 75mg (As enteric coated

pellets)

1

Capsule

M/s Synokem Pharmaceuticals Ltd.

/ M/s Aristo Pharmaceuticals Private Limited.

5.61

16.

Cefixime & Ofloxacin Tablet

Each film coated tablet contains: Cefixime IP as Trihydrate eq. to Anhydrous Cefixime 200mg Ofloxacin IP 200mg

1 Tablet

M/s Akums Drugs & Pharmaceuticals Ltd.

/M/s Mylan

Pharmaceuticals Private Limited.

11.47

17.

Azelnidipine + Telmisartan Tablets

Each film coated bi-layered tablet contains:

Azelnidipine IP 8mg, Telmisartan IP 40mg

1 Tablet

M/s Synokem Pharmaceuticals Ltd.

/ M/s Cipla Limited.

11.02

18.

Azelnidipine + Telmisartan Tablets

Each film coated bi-layered tablet contains:

Azelnidipine IP 8mg, Telmisartan IP 80mg

1 Tablet

M/s Synokem Pharmaceuticals Ltd.

/ M/s Cipla Limited.

13.22

19.

Glimepiride + Metformin Hydrochloride

prolonged release tablets

Each uncoated bi-layered tablet contains:

Glimepiride IP 4mg

Metformin Hydrochloride IP 500mg (In prolonged release form)

1 Tablet

M/s Skymap Pharmaceuticals Pvt. Ltd.

10.25

20.

Glimepiride + Metformin Hydrochloride prolonged release tablets

Each uncoated bi-layered tablet contains:

Glimepiride IP 4mg Metformin Hydrochloride IP

1000mg (In prolonged release form)

1 Tablet

M/s Skymap Pharmaceuticals Pvt. Ltd.

9.76

21.

Glimepiride + Metformin Hydrochloride

prolonged release tablets

Each uncoated bi-layered tablet contains:

Glimepiride IP 3mg

Metformin Hydrochloride IP 500mg (In prolonged release form)

1 Tablet

M/s Skymap Pharmaceuticals Pvt. Ltd.

8.41

22.

Glimepiride + Metformin Hydrochloride prolonged release tablets

Each uncoated bi-layered tablet contains:

Glimepiride IP 3mg Metformin Hydrochloride IP

1000mg (In prolonged release form)

1 Tablet

M/s Skymap Pharmaceuticals Pvt. Ltd.

9.35

23.

Telmisartan + Cilnidipine + Metoprolol Tablet (NEXOVAS TM 50)

Each film coated Bilayered tablet

contains:

Telmisartan IP 40mg, Cilnidipine IP 10mg

Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate (as extended release) 50mg

1 Tablet

M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd.

12.41

24.

Glimepiride + Metformin

Each uncoated bi-layered tablet contains:

1 Tablet

M/s Skymap Pharmaceuticals Pvt.

9.76

Sl. No

.

Name of the

Formulation / Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail

Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Hydrochloride prolonged release tablets

Glimepiride IP 4mg Metformin Hydrochloride IP

1000mg (In prolonged release form)

Ltd. / M/s Jagsonpal Pharmaceuticals Ltd.

25.

Glimepiride + Metformin Hydrochloride prolonged release

tablets

Each uncoated bi-layered tablet contains:

Glimepiride IP 4mg

Metformin Hydrochloride IP 500mg (In prolonged release form)

1 Tablet

M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd.

10.25

26.

Glimepiride + Metformin Hydrochloride prolonged release

tablets

Each uncoated bi-layered tablet contains:

Glimepiride IP 3mg

Metformin Hydrochloride IP 500mg (In prolonged release form)

1 Tablet

M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd.

8.41

27.

Glimepiride + Metformin Hydrochloride prolonged release tablets

Each uncoated bi-layered tablet contains:

Glimepiride IP 3mg Metformin Hydrochloride IP

1000mg (In prolonged release form)

1 Tablet

M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd.

9.35

28.

Escitalopram Oxalate + Clonazepam Tablets IP

Each film coated tablet contains:

Escitalopram Oxalate IP Eq. to Escitalopram 5mg, Clonazepam IP 0.25mg

1 Tablet

M/s Pure and Cure

Healthcare Pvt. Ltd.

/ M/s Aristo Pharmaceuticals

Private Limited.

6.73

29.

Escitalopram Oxalate + Clonazepam Tablets IP

Each film coated tablet contains: Escitalopram Oxalate IP Eq. to Escitalopram 5mg,

Clonazepam IP 0.5mg

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd.

/ M/s Aristo Pharmaceuticals

Private Limited.

7.40

30.

Escitalopram Oxalate + Clonazepam Tablets IP

Each film coated tablet contains: Escitalopram Oxalate IP Eq. to Escitalopram 10mg, Clonazepam IP 0.25mg

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd.

/ M/s Aristo

Pharmaceuticals Private Limited.

8.93

31.

Escitalopram Oxalate + Clonazepam Tablets IP

Each film coated tablet contains: Escitalopram Oxalate IP Eq. to Escitalopram 10mg, Clonazepam IP 0.5mg

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd.

/ M/s Aristo

Pharmaceuticals Private Limited.

10.79

32.

Ceftriaxone & Tazobactam for Injection 1125mg

Each vial contains:

Ceftiraxone Sodium IP (Sterile) eq. to Ceftriaxone 1g

Tazobactam Sodium (Sterile) eq. to Tazobactam 125mg

Each Pack

M/s Nitin Lifesciences Limited / M/s Mylan Pharmaceticals

Private Limited

146.32

33.

Moxifloxacin 0.5% w/v

+ Dexamethasone Phosphate 0.1% w/v Ophthalmic Solution

Each ml contains:

Moxifloxacin Hydrochloride IP eq. to Moxifloxacin 5.0mg Dexamethasone Sodium Phosphate IP eq. to

Dexamethasone Phosphate 1.0mg Water for Injections IP q. s. to 1ml

1 ML

M/s Micro Labs Limited

19.10

Sl. No

.

Name of the

Formulation / Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail

Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

34.

Metformin Hydrochloride prolonged release + Glimepiride tablet IP

Each uncoated bilayered tablet contains:

Metformin Hydrochloride IP (in prolonged release form) 500mg

Glimepiride IP 1mg

1 Tablet

M/s Inventia Healthcare Limited

5.95

35.

Metformin Hydrochloride prolonged release + Glimepiride tablet IP

Each uncoated bilayered tablet contains:

Metformin Hydrochloride IP (in

prolonged release form) 500mg Glimepiride IP 2mg

1 Tablet

M/s Inventia Healthcare Limited

7.73

36.

Metformin Hydrochloride prolonged release + Glimepiride tablet IP

Each uncoated bilayered tablet contains:

Metformin Hydrochloride IP (in

prolonged release form) 1000mg Glimepiride IP 1mg

1 Tablet

M/s Inventia Healthcare Limited

6.55

37.

Metformin Hydrochloride prolonged release + Glimepiride tablet IP

Each uncoated bilayered tablet contains:

Metformin Hydrochloride IP (in prolonged release form) 1000mg Glimepiride IP 2mg

1 Tablet

M/s Inventia Healthcare Limited

8.33

38.

Norethisterone Acetate Controlled release Tablets

Each film coated controlled release tablet Contains: Norethisterone Acetate BP 10 mg

1 Tablet

M/s Synokem Pharmaceuticals Ltd.

/ M/s Mankind Pharma Limited

15.09

39.

Norethisterone Acetate Controlled release Tablets

Each film coated controlled release tablet Contains: Norethisterone Acetate BP 15 mg

1 Tablet

M/s Synokem Pharmaceuticals Ltd.

/ M/s Mankind Pharma Limited

18.00

40.

Metformin Hydrochloride (SR) + Vildagliptin Tablet (VILDAMAC M SR

50/500)

Each uncoated bilayered tablet contains:

Metformin Hydrochloride IP 500mg

(As sustained release form) Vildagliptin 50mg

1 Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd.

6.86

41.

Metformin Hydrochloride (SR) + Vildagliptin Tablet (VILDAMAC M SR 50/1000)

Each uncoated bilayered tablet contains:

Metformin Hydrochloride IP 1000mg (As sustained release form)

Vildagliptin 50mg

1 Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd.

7.51

The notification further added;

(a) The manufacturer of the above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

nppaMacleods PharmaciplaMetformingliclazideAmlodipineAtorvastatinClopidogrelAspirinmylan
Medical Dialogues Team
Medical Dialogues Team
    Show Full Article
    Next Story

    Editorial

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    View All

    Journal Club Today

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Health News Today

    Health Bulletin 09/ May/ 2025

    Health Bulletin 09/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok